Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 51

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 51
---
 by the Company of a Derivative Loss of $287,053 recognized in the period ended in 2025.

Working Capital

|                     |     |   | March 31, 2025 |   |     |   | September 30, 2024 |   |
|:--------------------|:----|:--|---------------:|:--|:----|:--|-------------------:|:--|
| Current assets      |     | $ |        151,749 |   |     | $ |            143,351 |   |
| Current liabilities |     |   |      5,867,880 |   |     |   |          5,378,456 |   |
| Working capital     |     | $ |     (5,716,131 | ) |     | $ |         (5,235,105 | ) |

| 40 |

Working capital deficit increased by $ 481,026 from September 30, 2024 to March 31, 2025, primarily due to increase in Derivative Liability.

|                                                      |     | Six Months Ended 
 March 31,        |     2025 |   |     |   |     2024 |   |
|:-----------------------------------------------------|:----|:-----------------|---------:|:--|:----|:--|---------:|:--|
| Net cash used in operating activities                |     | $                | (167,609 | ) |     | $ | (371,658 | ) |
| Net cash provided by financing activities            |     |                  |  168,655 |   |     |   |  328,734 |   |
| Net increase (decrease) in cash and cash equivalents |     | $                |    1,045 |   |     | $ |  (42,934 | ) |
| Cash, beginning of period                            |     |                  |      716 |   |     |   |  121,037 |   |
| Cash, end of period                                  |     | $                |    1,761 |   |     | $ |   78,114 |   |

Liquidity and Capital Resources

Operating Activities

Net cash used in operating activities for the six months ended March 31, 2025 was $167,609, compared to $371,658, for the same period ended 2024, a decrease of $204,049. The decrease in cash used